阅读说明：本技术 白头翁皂苷b4在制备治疗糖尿病及其并发症药物中的应用 (Application of pulsatilla saponin B4 in preparation of medicine for treating diabetes and complications thereof ) 是由 刘艳丽 许琼明 郝丽莉 何鸾 于 2019-11-29 设计创作，主要内容包括：本发明涉及白头翁皂苷B4在制备治疗和/或预防糖尿病及其并发症药物中的应用。本发明公开了白头翁皂苷B4的新用途,为开发治疗糖尿病及其并发症的药物提供了新方向。(The invention relates to application of pulsatilla saponin B4 in preparing a medicine for treating and/or preventing diabetes and complications thereof. The invention discloses a new application of pulsatilla chinensis saponin B4, and provides a new direction for developing a medicine for treating diabetes and complications thereof.)

1. Application of pulsatilla saponin B4 in preparing medicine for treating and/or preventing diabetes is provided.

2. Use according to claim 1, characterized in that: the diabetes is type I or type II diabetes.

3. Use according to claim 1, characterized in that: the dosage of the pulsatilla chinensis saponin B4 is once or twice a day, and each time is 0.1-200 mg/kg.

4. Application of pulsatilla saponin B4 in preparing medicine for treating and/or preventing diabetic complication is provided.

5. The use according to claim 4, wherein the diabetic complication is selected from one or more of diabetic nephropathy, diabetic peripheral neuropathy, diabetic liver injury, diabetic eye disease and dyslipidemia.

6. The use according to claim 4, wherein the diabetic complication is selected from one or more of weight loss due to diabetes, renal edema, liver hypertrophy, impairment of renal function, hyperlipidemia, impairment of liver function, and diabetic cataract.

7. The use of claim 4, wherein the dose of pulsatillae radix saponin B4 is 0.1-200mg/kg once or twice a day.

Technical Field

The invention relates to application of pulsatilla chinensis saponin B4, in particular to application of pulsatilla chinensis saponin B4 in preparation of a medicine for treating and/or preventing diabetes and complications thereof.

Background

Diabetes Mellitus (DM) is a disease mainly characterized by hyperglycemia caused by absolute or relative insufficiency of insulin secretion and/or insulin action, and can be divided into type I diabetes mellitus and type II diabetes mellitus, wherein the pathogenesis of the type I diabetes mellitus is that autoimmunity destroys pancreas β cells, so that absolute deficiency of insulin secretion is caused, a patient can keep life only by injecting insulin, the type I diabetes mellitus patients account for about 10% of the total number of the diabetes mellitus patients and are mostly children or teenagers, the type II diabetes mellitus is also called non-insulin-dependent diabetes mellitus and is related to β cell dysfunction and insulin resistance and is influenced by genetic factors and environmental factors, the number of the patients accounts for more than 90% of the diabetes mellitus patients, most of the middle-aged and old people can be treated by taking sugar-reducing medicaments and reasonable exercise diets, the incidence and the mortality of the diabetes mellitus and the complication of the diabetes mellitus are increased year by year, and the diabetes mellitus and the death rate of the human beings are mainly threatened to be promoted and live.

Clinically, patients with diabetes mainly show hyperglycemia, hyperlipidemia and hyperinsulinemia, and are accompanied by symptoms of polydipsia, polyphagia, polyuria, weight loss and the like. Meanwhile, the large blood vessels and the micro blood vessels in the body of the patient are damaged due to long-term high blood sugar level, so that tissues such as heart, brain, liver, kidney, eyes, feet, peripheral nerves and the like are further endangered, and a series of complications are caused. According to the statistics of the world health organization, the diabetic complications are hundreds of types, and are the most known diseases at present.

Among them, Diabetic Nephropathy (DN) is a type of diabetic complication with high incidence, the incidence rate of which is increasing every year, and the main clinical manifestations of diabetic nephropathy are chronic hyperglycemia and proteinuria. About 30% of type I diabetic patients and 25% of type II diabetic patients have a serious impact on the life of diabetic patients on diabetic nephropathy. The diabetic nephropathy is a result of the combined action of multiple factors, the pathogenesis of the diabetic nephropathy is very complex and not completely clear, and the key relevant factors discovered at present mainly comprise the following factors: high sugar, hyperlipidemia, ischemia and anoxia, mechanical injury and hemodynamic changes can cause endothelin increase, further affect the hemodynamic of kidney and accelerate kidney injury.

If the effective treatment is not obtained, the disease is easy to progress into uremia, great threat is caused to the life health of patients, great economic burden is brought to families of the patients, and no specific treatment method exists at present.

In addition, Diabetic Retinopathy (DR) is a common complication in diabetic complications and is the leading cause of blindness in young and middle-aged working people all over the world at present. The main reason for the occurrence of the disease is that the visual function of patients is damaged by hyperglycemia, hypertension and hyperlipidemia, so that the retinal microvascular disease is caused. Blindness and renal failure and even death in diabetic patients are due to the fact that areas of microvascular disease in diabetic patients occur primarily in the retina as well as in the kidney. Symptoms such as aneurysm, bleeding spot, lint spot, intraretinal microvascular abnormality and macular edema are all pathological manifestations of retinal capillaries in diabetic patients. Retinal blood vessels, pre-retinal hemorrhage, optic disc neovascularization and even tractional retinal detachment can be caused by ischemia of the eye, and finally, the patient has serious visual impairment.

However, up to now, there is no method for completely curing diabetes, and only exercise or drug measures are taken to control blood sugar, or drugs are used to inhibit the occurrence of diabetic complications. Some of the presently disclosed pharmaceutical compositions for treating diabetes and its complications are generally traditional Chinese medicine compositions, such as those disclosed in CN02110059.4, CN201110432832.7, CN201210084774.8 and CN 200910300451.6. However, it is not known which ingredients of the composition exert the primary therapeutic effect. In addition, some plant extracts are applied to the medicines for treating diabetes and complications thereof, for example, CN200310105686.2 discloses the application of arctiin and arctigenin thereof in preparing the medicines for treating diabetes and complications thereof, CN201310167424.2 discloses the application of berberine and panax notoginseng saponins in preparing the medicine composition for treating diabetes and complications thereof, and CN201310355556.8 discloses the application of yam total saponins in preparing the medicines for treating diabetes and complications thereof. Therefore, there is a need to develop new drugs for treating diabetes and its complications.

Disclosure of Invention

In order to solve the technical problems, the invention aims to provide application of pulsatilla saponin B4 in preparation of medicines for treating and/or preventing diabetes and complications thereof.

The technical scheme of the invention is as follows:

in one aspect, the invention discloses application of pulsatilla saponin B4 in preparing a medicament for treating and/or preventing diabetes.

Further, the diabetes is type I or type II diabetes.

Further, the dosage of the pulsatilla saponin B4 is once or twice a day, and each time is 0.1-200 mg/kg.

On the other hand, the invention also discloses application of the pulsatilla saponin B4 in preparing a medicine for treating and/or preventing diabetic complications.

Furthermore, the diabetic complication is one or more selected from diabetic nephropathy, diabetic peripheral neuropathy, diabetic liver injury, diabetic eye disease, and blood lipid metabolism disorder.

Further, the diabetic complication is one or more selected from weight loss caused by diabetes, renal edema, liver hypertrophy, renal function damage, hyperlipidemia, liver function damage and diabetic cataract.

Further, the dosage of the pulsatilla saponin B4 is one or two times, and each time is 0.1-200 mg/kg. .

In the invention, the structural formula of the pulsatilla saponin B4 is as follows:

by the scheme, the invention at least has the following advantages:

the invention discloses a new application of pulsatilla chinensis saponin B4, and provides a new direction for developing a medicine for treating diabetes and complications thereof.

The foregoing description is only an overview of the technical solutions of the present invention, and in order to make the technical solutions of the present invention more clearly understood and to implement them in accordance with the contents of the description, the following description is made with reference to the preferred embodiments of the present invention and the accompanying detailed drawings.

Drawings

FIG. 1 is a graph showing the effect of pasqueflower saponin B4 on the body weight of diabetic rats;

FIG. 2 is a graph showing the effect of Pulsatillae saponin B4 on the water diet of diabetic rats;

FIG. 3 is a graph showing the effect of pasqueflower saponin B4 on the organ index of diabetic rats;

FIG. 4 is a graph showing the effect of pasqueflower saponin B4 on biochemical markers of diabetic rats;

FIG. 5 is a schematic representation of a normal, non-cataractous eye and varying degrees of cataract;

FIG. 6 shows the results of HE staining, polysaccharide matrix deposition and Masson trichrome staining of rat kidney tissue;

FIG. 7 is a graph showing a statistical graph of pathological changes of Pulsatillae saponin B4 on kidney of diabetic rat.

Detailed Description

The following examples are given to further illustrate the embodiments of the present invention. The following examples are intended to illustrate the invention but are not intended to limit the scope of the invention.